Yanqi Lan

Yanqi Lan

Auto-generated profile, based on publicly available information

Yanqi Lan

Xiamen Center for Disease Control and Prevention, Xiamen, Fujian, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
YLYanqi Lan
Yanqi Lan
SWShouling Wu
Shouling Wu
YWYanhong Wang
Yanhong Wang
SCShuohua Chen
Shuohua Chen
WLWei Liao
Wei Liao
LWLi Wang
Li Wang

25 October 2022 in Hepatology Communications
Verified
Journal Article
Open access
YLYanqi Lan
Yanqi Lan
YLYing Lu
Ying Lu
JLJin-Feng Li
Jin-Feng Li
SHShiqi Hu
Shiqi Hu
SCShuohua Chen
Shuohua Chen
LWLi Wang
Li Wang
The ability to determine the prognosis of lean nonalcoholic fatty liver disease (NAFLD) is essential for decision making in clinical settings. Using a large community‐based Chinese cohort, we aimed to investigate NAFLD outcomes by body mass index (BMI). We used the restricted cubic splines method to investigate the dose–response relationship between BMI and outcomes in subjects with NAFLD and those without NAFLD. We included 73,907 subjects from the Kailuan cohort and grouped all subjects into four phenotypes by using NAFLD and BMI (<23 kg/m2). The probability of developing outcomes for individuals with lean NAFLD (LN), overweight/obese NAFLD (ON), overweight/obese non‐NAFLD (ONN), and lean non‐NAFLD (LNN) was estimated. We found a U‐shaped association between BMI and death but a linear positive association concerning cardiovascular disease (CVD) after adjusting for age and other covariates. Compared with the LNN group, the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of the LN, ON, and ONN groups were 1.30 (1.14–1.49), 0.86 (0.80–0.91), 0.84 (0.80–0.89) for all‐cause death, 2.61 (1.13–6.03), 0.74 (0.44–1.26), 1.10 (0.70–1.74) for liver‐related death, 2.12 (1.46–3.08), 1.23 (0.99–1.54), 1.19 (0.98–1.43) for digestive system cancers, and 2.04 (1.40–2.96), 1.30 (1.05–1.61), 1.21 (1.01–1.46) for obesity‐related cancers. Subjects with LN had a significantly higher risk of colorectal cancer and esophagus cancer. However, the ON group had the highest CVD risk (HR, 1.39; 95% CI, 1.27–1.52). The LN group with hypertension had a higher risk of adverse outcomes, and those without hypertension had a similar risk compared to LNN. Conclusion: Subjects with LN may experience a higher risk of all‐cause death, digestive system cancers, and obesity‐related cancers than the other three groups but a lower risk of CVD than ON subjects. LN with hypertension may be a high‐risk phenotype.

5 April 2024 in Digestive and Liver Disease
Verified
Journal Article
Closed access
YLYanqi Lan
Yanqi Lan
ZGZhinan Guo
Zhinan Guo
JDJunsheng Dai
Junsheng Dai
KCKailin Chen
Kailin Chen
YCYoulan Chen
Youlan Chen